Market Place
Sourcing Support
Melt Pharmaceuticals Reports Positive Phase 3 Results for MELT-300
20 Nov 2024 //
BUSINESSWIRE
Melt Completes Dosing In MELT-300 Phase 3 For Cataract Surgery
10 Oct 2024 //
BUSINESSWIRE
Melt Pharmaceuticals Announces First Patient Dosed In Pivotal Phase 3 Program
06 Jun 2024 //
BUSINESSWIRE
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
02 Apr 2024 //
BUSINESSWIRE
Melt Pharmaceuticals Provides Corporate Update
03 Jan 2024 //
BUSINESSWIRE
Melt Pharmaceuticals Announces License Agreement with Catalent
26 Sep 2023 //
BUSINESSWIRE
Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint
21 Dec 2022 //
BUSINESSWIRE
Melt Announces Dosing of Last Patient in Phase 2 Efficacy Study for MELT-300
27 Oct 2022 //
BUSINESSWIRE
Melt Pharma Announces MELT-210 Top-Line Results of Phase 1 PK Study
04 May 2022 //
BUSINESSWIRE
Melt Pharmaceuticals Names Experienced Executive Brad Osborne as CFO
10 Mar 2022 //
BUSINESSWIRE
Melt Pharmaceuticals Submits INDs for MELT?210 and MELT-400 to FDA
04 Jan 2022 //
BUSINESSWIRE
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
02 Sep 2021 //
BUSINESSWIRE
Melt Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug
09 Feb 2021 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.